On October 7, 2025, Andrew Dreyfus announced his resignation from Ironwood Pharmaceuticals' Board, effective November 1, 2025, to become CEO of the NIHCM Foundation, with no disagreements reported. The company expressed gratitude for his contributions during his tenure.